Charles River Laboratories International (NYSE:CRL – Get Rating) and OmniAb (NASDAQ:OABI – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
Analyst Ratings
This is a summary of recent ratings and target prices for Charles River Laboratories International and OmniAb, as reported by MarketBeat.
Get
Charles River Laboratories International alerts:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Charles River Laboratories International | 0 | 2 | 11 | 0 | 2.85 |
| OmniAb | 0 | 0 | 4 | 0 | 3.00 |
Charles River Laboratories International currently has a consensus target price of $298.42, indicating a potential upside of 31.03%. OmniAb has a consensus target price of $10.25, indicating a potential upside of 195.39%. Given OmniAb's stronger consensus rating and higher possible upside, analysts clearly believe OmniAb is more favorable than Charles River Laboratories International.
Profitability
This table compares Charles River Laboratories International and OmniAb's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Charles River Laboratories International | 11.54% | 20.93% | 7.53% |
| OmniAb | N/A | N/A | -3.50% |
Volatility and Risk
Charles River Laboratories International has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, OmniAb has a beta of -1.19, suggesting that its stock price is 219% less volatile than the S&P 500.
Institutional & Insider Ownership
97.8% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 42.3% of OmniAb shares are held by institutional investors. 1.1% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Charles River Laboratories International and OmniAb's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Charles River Laboratories International | $35.40 billion | 0.33 | $390.98 million | $8.49 | 26.83 |
| OmniAb | N/A | N/A | -$520,000.00 | N/A | N/A |
Charles River Laboratories International has higher revenue and earnings than OmniAb.
Summary
Charles River Laboratories International beats OmniAb on 9 of the 11 factors compared between the two stocks.
About Charles River Laboratories International
(Get Rating)
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
About OmniAb
(Get Rating)
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
